Frontiers in Medicine (Feb 2022)

Changes in Serum Neutralizing Antibodies Levels During Convalescence of COVID-19 Patients

  • Qing-Qing Chen,
  • Qing-Qing Chen,
  • Lei Gong,
  • Lei Gong,
  • Xiao-Min Wu,
  • Xiao-Min Wu,
  • Ya-Ting Feng,
  • Ya-Ting Feng,
  • Wan-Rong Luo,
  • Wan-Rong Luo,
  • Xue Zhou,
  • Xue Zhou,
  • Yuan Yuan,
  • Yuan Yuan,
  • Jun-Ling Yu,
  • Jun-Ling Yu,
  • Lan He,
  • Lan He,
  • Peng Wang,
  • Peng Wang,
  • Ying-Lu Ge,
  • Ying-Lu Ge,
  • Sai Hou,
  • Sai Hou,
  • Wei-Wei Li,
  • Wei-Wei Li,
  • Yong Sun,
  • Yong Sun,
  • Jia-Bing Wu,
  • Jia-Bing Wu,
  • Bin Su,
  • Bin Su,
  • Hai-Feng Pan,
  • Hai-Feng Pan,
  • Jun He,
  • Jun He,
  • Jun He,
  • Zhi-Rong Liu,
  • Zhi-Rong Liu

DOI
https://doi.org/10.3389/fmed.2022.829273
Journal volume & issue
Vol. 9

Abstract

Read online

Detection of serum-specific SARS-CoV-2 antibody has become a complementary means for the identification of coronavirus disease 2019 (COVID-19). As we already know, the neutralizing antibody titers in patients with COVID-19 decrease during the course of time after convalescence, whereas the duration of antibody responses in the convalescent patients has not been defined clearly. In the current study, we collected 148 serum samples from 37 confirmed COVID-19 cases with different disease severities. The neutralizing antibodies (Nabs), IgM and IgG against COVID-19 were determined by CLIA Microparticle and microneutralization assay, respectively. The time duration of serum titers of SARS-CoV-2 antibodies were recorded. Our results indicate that IgG (94.44%) and Nabs (89.19%) can be detected at low levels within 190–266 days of disease onset. The findings can advance knowledge regarding the antibody detection results for COVID-19 patients and provide a method for evaluating the immune response after vaccination.

Keywords